Aclaris Therapeutics (NASDAQ:ACRS) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a $16.00 price target on the biotechnology company’s stock.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.75.

Aclaris Therapeutics Trading Down 9.3%

ACRS stock opened at $3.51 on Wednesday. The firm has a 50 day moving average of $3.07 and a 200-day moving average of $2.33. The company has a market cap of $380.31 million, a price-to-earnings ratio of -2.54 and a beta of 0.41. Aclaris Therapeutics has a 12-month low of $1.05 and a 12-month high of $4.89.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.01. The firm had revenue of $3.30 million during the quarter, compared to the consensus estimate of $1.59 million. Aclaris Therapeutics had a negative return on equity of 39.73% and a negative net margin of 900.01%. Sell-side analysts forecast that Aclaris Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ACRS. JPMorgan Chase & Co. lifted its holdings in Aclaris Therapeutics by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 758,576 shares of the biotechnology company’s stock valued at $1,441,000 after purchasing an additional 134,784 shares in the last quarter. Qube Research & Technologies Ltd lifted its stake in shares of Aclaris Therapeutics by 7.0% during the third quarter. Qube Research & Technologies Ltd now owns 544,760 shares of the biotechnology company’s stock valued at $1,035,000 after buying an additional 35,410 shares during the period. Palo Alto Investors LP lifted its stake in shares of Aclaris Therapeutics by 12.7% during the third quarter. Palo Alto Investors LP now owns 1,566,840 shares of the biotechnology company’s stock valued at $2,977,000 after buying an additional 176,812 shares during the period. Citadel Advisors LLC boosted its position in Aclaris Therapeutics by 25.3% during the third quarter. Citadel Advisors LLC now owns 1,432,677 shares of the biotechnology company’s stock worth $2,722,000 after acquiring an additional 288,871 shares during the last quarter. Finally, Algert Global LLC grew its stake in Aclaris Therapeutics by 64.7% in the 3rd quarter. Algert Global LLC now owns 65,630 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 25,780 shares during the period. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.